Month: May 2023

EVERGREEN CORPORATION WITHDRAWS PROPOSALS PRESENTED AT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

Written by Customer Service on May 11, 2023. Posted in Public Companies.

KUALA LUMPUR, MALAYSIA, May 11, 2023 (GLOBE NEWSWIRE) — Evergreen Corporation (Nasdaq: EVGR) (the “Company”) today announced that is withdrawing from consideration by the shareholders of the Company the proposals (the “Proposals”) set forth in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 2, 2023, as amended and supplemented on May 3, 2023, May 4, 2023 and May 5, 2023. The Company will continue to search for an initial business combination in accordance with its existing amended and restated articles and memorandum of association and the investment management trust agreement, dated as of February 8, 2022, by and between the Company and Continental Stock Transfer & Trust Company. Accordingly, the Company will deposit $1,150,000 for an additional three month...

Form 8.3 – Civitas Social Housing PLC

Written by Customer Service on May 11, 2023. Posted in Mergers And Acquisitions.

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Civitas Social Housing PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening...

DIVERGENT Energy Services Announces the Release of 2023 First Quarter Results

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, May 11, 2023 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (DVG: TSX-V) (“Divergent”, the “Company“, or “DVG”) announces the release of its financial results for the three ended March 31, 2023. All amounts are in thousands (000’s) of United States Dollars, unless otherwise noted. HIGHLIGHTS FOR THE QUARTER$3.1 million of revenue for the first quarter is a 19% increase over the prior year’s first quarter. Adjusted EBITDA of $408 in the first quarter is a 9% increase over the prior year’s first quarter. Q1 2023 is the tenth consecutive quarter of positive Adjusted EBITDA. Gross margin percentage of 31% for the first quarter.INDUSTRY OUTLOOK Global demand for oil remains strong as the world’s major economies continue to rely on petroleum products in everyday life. Macroeconomic factors...

Kelso Technologies Inc. Financial Results for the Three Months Ended March 31, 2023

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia and BONHAM, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) reports that it has released its unaudited consolidated interim financial statements and Management Discussion and Analysis for the three months ended March 31, 2023. The unaudited consolidated interim financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). All amounts herein are expressed in United States dollars (the Company’s functional currency) unless otherwise indicated. The Company’s unaudited consolidated financial statements and MD&A for the three months ended March 31, 2023 were approved by the Board of Directors on May 10, 2023. SUMMARY...

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022. The following are 2023 first quarter highlights:On January 19, 2023, Sunshine Biopharma announced a stock repurchase program of up to $2 million under SEC Rule 10B-18. During the three months ended March 31, 2023, the Company repurchased a total of 445,711...

Exela Technologies, Inc. Reports First Quarter 2023 Results

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

First Quarter HighlightsRevenue of $273.6 million, down 2.1% year-over-year (0.9% on a constant currency basis) Net loss of $45.4 million Gross profit(1) of $57.2M, up $9M sequentially and gross margin improved to 20.9% Adjusted EBITDA of $34.7M $64.9M new TCV and renewal of $43.3M TCV reflect strength of award-winning best-in-class solutions and services Value enhancing initiatives: Project Neon, XBP Europe and Recapitalization of Debt progressing Results of the Special Meeting of Shareholders to be announced by May 12, 2023Conference call scheduled for May 11, 2023 at 9:00 AM ET IRVING, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA, XELAP), a global business process automation (“BPA”) leader, announced today its financial results for first quarter ended March 31,...

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Written by Customer Service on May 11, 2023. Posted in Public Companies.

Pivotal top-line data readout expected in mid-2023 WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. “The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® development program and we look forward to the availability of top-line results from this important...

Venus Concept Announces 1-for-15 Reverse Stock Split

Written by Customer Service on May 11, 2023. Posted in Public Companies.

TORONTO, May 11, 2023 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that its Board of Directors approved a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective at 5:00 p.m. Eastern Daylight Time today. The Company’s common stock is expected to begin trading on The Nasdaq Capital Market on a split-adjusted basis at the open of trading on May 12, 2023. The Company’s stockholders previously approved the Reverse Stock Split at the annual and special meeting of stockholders held on May 10, 2023 at a ratio ranging from 1-for-5 up to a ratio of 1-for-15, such ratio and the implementation and timing of such Reverse Stock Split to be...

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

Written by Customer Service on May 11, 2023. Posted in Public Companies.

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults. The STRIVE sub-protocol trial is the first to initiate under Vir’s new PREVAIL platform trial evaluating VIR-2218 and VIR-3434 with other therapies, including PEG-IFNα and an NRTI, in people at...

UCLOUDLINK GROUP INC. to Report First Quarter 2023 Financial Results on May 18, 2023

Written by Customer Service on May 11, 2023. Posted in Public Companies.

Earnings Call Scheduled for 8:30 a.m. Eastern Time on Thursday, May 18, 2023 HONG KONG, May 11, 2023 (GLOBE NEWSWIRE) — UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the first quarter of 2023 before the market open on Thursday, May 18, 2023. Management will hold a conference call to discuss these results at 8:30 a.m. Eastern Time / 8:30 p.m. Beijing Time the same day. Listeners may access the call by dialing:International: +1-412-902-4272US (Toll Free): +1-888-346-8982UK (Toll Free) 0-800-279-9489UK (Local Toll) 0-207-544-1375Mainland China (Toll Free): 400-120-1203Hong Kong (Toll Free): 800-905-945Hong Kong (Local Toll): +852-3018-4992Singapore...

Month: May 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals